Symphogen is leading the development of antibody mixture therapeutics to improve the treatment of cancer.
Symphogen's growing pipeline of cancer programs reflects a new approach to fighting cancer with unique mechanisms based on multiple simultaneous attacks on tumors. The result is improved efficacy and the potential to reduce the development of drug resistance.
- Symphogen's founding CEO Kirsten Drejer steps down and becomes Executive Director
- Symphogen announces the appointment of Jeffrey H. Buchalter and Christoffer Søderberg as Non-Executive Directors
- Symphogen Initiates Anti-MET Clinical Program And Presents Pre-Clinical Anti-MET Data at Annual AACR Meeting April 18th in New Orleans
- More news